Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asmacure Ltee, a developer of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, has named Martin Driscoll as the new CEO.
Subscribe to our email newsletter
Before joining Asmacure, Driscoll served as the CEO and director of Javelin Pharmaceuticals, a developer of acute care pain products.
Prior to Javelin, Driscoll held senior positions in Schering-Plough, ViroPharma and Reliant Pharmaceuticals.
Driscoll said he is looking forward to closely working with the Asmacure team as they lead the company through this exciting time of development and growth.